PMN
ProMIS Neurosciences, Inc. (PMN) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
ProMIS Neurosciences’ environmental risk profile is currently moderate, reflecting its early-stage operations and lack of manufacturing. However, the absence of sustainability reporting and climate strategy is a gap relative to best-in-class biotech peers.
Social
ProMIS demonstrates strong social performance through its patient-centric clinical development, focus on high unmet needs, and transparent stakeholder engagement. Continued safety and efficacy in trials will be critical to maintaining this position.
Governance
Governance is moderate, with recent board enhancements and regulatory compliance actions. However, financial sustainability remains a key risk until clinical milestones are achieved and commercial revenues are established.
Overall Score
ProMIS Neurosciences exhibits moderate overall ESG performance. Social factors are strong due to patient safety and innovation, while governance is supported by board improvements and compliance actions. Environmental risks are currently limited but lack proactive management. The company’s ESG profile will depend on its ability to maintain clinical progress, strengthen sustainability practices, and achieve financial resilience.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on ProMIS Neurosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.